John L. Higgins - Dec 12, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
/s/ Andrew Reardon, Attorney-in-Fact for John L. Higgins
Stock symbol
LGND
Transactions as of
Dec 12, 2022
Transactions value $
$29
Form type
4
Date filed
12/14/2022, 04:00 PM
Previous filing
Dec 1, 2022
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $256K +20K +4.8% $12.78* 437K Dec 12, 2022 Direct
transaction LGND Common Stock Disposed to Issuer -$256K -3.94K -0.9% $64.80 433K Dec 12, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -20K -49.58% $0.00 20.3K Dec 12, 2022 Common Stock 20K $12.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The original date of grant was 02/15/13.